The colourful past and bright future of monoamine oxidase research; radical thoughts about the life of MAO; redox properties of flavin cofactor of monoamine oxidases A and B and their relationship to the kinetic mechanism; stereochemistry and cofactor identity status of semicarbazide-sensitive amine oxidases; expression of human monoamine oxidase (MAO) A gene controlled by transcription factor Sp1.; the promoter of the human monoamine oxidase A gene; analysis of MAO-A mutations in humans; the correlation between platelet MAO activity and personality: short review of findings and a discussion on possible mechanism; platelet MAO activities and MAO-B protein concentrations in Parkinson's disease and controls; aromatic L-amino acid decarboxylase modulation and Parkinson's disease; some new mechanism underlying the actions of (-)-deprenyl: possible relevance to neurogeneration; neurochemical, neuroprotective and neurorescue effects of aliphatic N-methylpropargylamine: new MAO-B inhibitors without amphetamine-like properties; enentioselective recognition of two anticonvulsants, FCE 26743 and FCE 28073, by MAO, and relationship between MAO-B inhibition and FCE 26743 concentrations in rat brain; Selectivity of MDL-72,974A for MAO-B inhibition based on substrate and metabolite concentrations in plasma; the distribution of orally administered (-)-deprenyl-propenyl-14C and (-)deprenyl-phenyl-3H in rat brain; novel sites of action for deprenyl in MPTP-Parkinsonism: metabolite mediated protection against striatal neurotoxicity and suppression of MPTP-induced increase of dopamine turnover in C5BL mice; effects of transient global ischemia and a monoamine oxidase inhibitor ifenprodil on rat brain monoamine metabolism; effects of MAO inhibitor phenelzine on glutamine and GABA concentrations in rat brain; metabolism of agmatine (clonidine-displacing substance) by diamine oxidase and the possible implications for studies of imidazoline receptors; increase of survival of dopaminergic neuroblastoma in co-cultures with C-6 glioma by R(-)-deprenyl; canine pituitary-dependent hyperadrenocorticism: a spontaneous animal model for neurodegenerative disorders and their treatment with l-deprenyl; canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer's disease: clinical presentation, cognitive testing, pathology and response to l-deprenyl therapy; dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines, oxidation and neurotoxicity; monoamines, cytoskeletal elements and psychiatric disorders, a neurochemical fugue. (Part contents).
